Posters present data on utility of cfDNA for patient mutation load in NSCLC; cfRNA PD-L1 + MSI single-blood-tube testing; and innovative salvage of buccal NGS testing BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, advancing precision medicine through personalized [...]
CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]
REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by CIRCULOGENE, this pilot [...]
Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference Research involving Circulogene’s single-drop-volume liquid biopsy assays for real-time monitoring of cancer mutations included in ASCO 2016 BIRMINGHAM, Ala., May 20, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology [...]
AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations Interlab comparison demonstrates Circulogene’s blood-drop-volume liquid biopsy assay is fastest, most accurate process to date for tracking and treating cancer BIRMINGHAM, Ala., – [...]
Circulogene Theranostics Liquid Biopsy Research Accepted for Abstract Presentation at AACR Annual Meeting Researchers to present clinical study data on next-generation sequencing for blood-drop liquid biopsy BIRMINGHAM, Ala., February 17, 2016 (BUSINESS WIRE) – Circulogene Theranostics announced [...]
Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement BIRMINGHAM, Ala., February 10, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop for patient-specific [...]
Birmingham Business Journal reported on Birmingham's latest breakthrough biotechnology company, Circulogene Theranostics and their recent surge of local investment. The article includes interviews with Mike Mullen, CEO and President, Dr. Chen Hsiung-Yeh, Chief Scientific Officer, [...]
MOJ Cell Science & Report published an editorial written by Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh, on Next-Generation Sequencing and Targeted Cancer Therapy. The complex nature of cancer and the transformation of cancer care, [...]
Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh's research, was recently featured in the Journal of Cancer Prevention & Current Research, Volume 3 Issue 1 - 2015 It is in agreement and the growing belief that [...]
